Researchers have designed a nanoparticle-based therapy that is effective in treating mice with multiple myeloma, a cancer of bone marrow immune cells. Targeted specifically to the malignant cells, these nanoparticles protect their therapeutic cargo from degradation in the bloodstream and greatly enhance drug delivery into the cancer cells.
The Food and Drug Administration (FDA) has approved for testing in people a nanoparticle-based imaging agent jointly developed at the School of Medicine and collaborating institutions. The imaging agent may illuminate dangerous plaque in arteries, and doctors hope to use it to identify patients at high risk of stroke.
Samuel A. Wickline, MD, has been chosen to receive the Chancellor’s Award for Innovation and Entrepreneurship at Washington University in St. Louis. He will receive the honor Saturday, Dec. 6. Faculty achievement awards will be presented to David A. Balota, PhD, and Steven L. Teitelbaum, MD.